SCHEMBL5584115

SCHEMBL5584115

CC1CC(=Cc2ccccc2O)C(=O)O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 3/20 0.51
DYRK1B Q9Y463 3/20 0.51
CLK1 P49759 2/20 0.51
MAOA P21397 5/20 0.49
MAOB P27338 5/20 0.49
PIK3CA P42336 1/20 0.48
DYRK2 Q92630 1/20 0.48
MIF P14174 4/20 0.47
NAT1 P18440 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KMT2A Q03164 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TRIM24 O15164 1/20 0.39
TRIM33 Q9UPN9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14571667 1.00 DYRK1A (0.51) DYRK1ADYRK1BCLK1MAOAMAOB
SCHEMBL11831810 0.81 DYRK2 (0.51) DYRK1ADYRK1BCLK1MAOAPIK3CA
SCHEMBL9543178 0.78 MAPT (0.53) MIFNAT1KDM4EPOLBMAPT
SCHEMBL981312 0.77 DYRK1A (0.69) DYRK1ADYRK1BCLK1MAOAMAOB
SCHEMBL9448646 0.72 MIF (0.49) MIFNAT1KDM4EMAPTMEN1
SCHEMBL11303976 0.72 DYRK1A (0.48) DYRK1ADYRK1BCLK1MAOAMAOB
SCHEMBL7132282 0.70 IKBKB (0.65) MAOAMAOBMIFNAT1MAPT
SCHEMBL5585089 0.70 ALDH1A1 (0.61) DYRK1ADYRK1BCLK1DYRK2MIF
SCHEMBL14571661 0.70 ALDH1A1 (0.61) DYRK1ADYRK1BCLK1DYRK2MIF
SCHEMBL17691431 0.70 IKBKB (0.65) MAOAMAOBMIFNAT1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A DYRK1A 958/4885DYRK1B 1061/4885CLK1 2498/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A DYRK1A 958/4885DYRK1B 1061/4885CLK1 2498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.